New Strain Construction and Screening Tests: Methods, Standards, and Industrial Applications

New strain construction and screening tests deliver systematic laboratory workflows for engineering microbial genomes and identifying high-performance variants for industrial biotechnology. By integrating rational genetic engineering, mutagenesis, high-throughput screening, and validated analytical verification, these services help developers of enzymes, amino acids, biologics, and probiotics convert candidate strains into scalable production platforms. All evaluations are performed by accredited third-party laboratories in accordance with recognized international standards to ensure data integrity, biosafety, and regulatory compliance.

Technical Overview

New strain construction and screening tests encompass the complete Design-Build-Test-Learn (DBTL) cycle used to create and evaluate genetically improved microorganisms. Strain construction refers to the deliberate modification of a microbial genome through targeted genetic engineering or genome-wide mutagenesis, with the goal of enhancing productivity, substrate utilization, stress tolerance, or product purity. Screening refers to the systematic evaluation of constructed or mutated strain populations to isolate the variants that exhibit the desired phenotype at laboratory and pilot scale.

A typical program proceeds through several linked phases: target gene identification and pathway design, molecular construction and transformation, primary screening of large variant libraries, secondary confirmation in shake-flask or small bioreactor cultures, and final verification of genotype, genetic stability, and biosafety attributes. Each phase relies on documented operating procedures, qualified culture media prepared in accordance with ISO 11133, and microbiological work practices aligned with ISO 7218 and applicable GB laboratory biosafety requirements.

• Construction routes: CRISPR-Cas genome editing, homologous recombination, recombineering, transposon insertion, and physical or chemical mutagenesis
• Screening tiers: plate-based primary screens, microplate high-throughput assays, and controlled fermentation confirmation
• Verification scope: genotype confirmation, expression analysis, product titer, growth kinetics, and passage stability

Testing Samples

Bacterial Platform Strains

Common bacterial hosts submitted for construction and screening include Escherichia coli, Bacillus subtilis, Bacillus licheniformis, Corynebacterium glutamicum, Streptomyces species, Pseudomonas putida, and lactic acid bacteria such as Lactobacillus and Lactococcus species. Samples may be received as glycerol stocks, agar slants, lyophilized vials, or actively growing cultures, accompanied by documented strain history and biosafety classification.

Yeast and Filamentous Fungal Strains

Eukaryotic platforms cover Saccharomyces cerevisiae, Komagataella phaffii (Pichia pastoris), Yarrowia lipolytica, and filamentous fungi such as Aspergillus, Trichoderma, and Penicillium species. These hosts are frequently engineered for secreted enzymes, organic acids, and recombinant proteins, and require tailored transformation and screening protocols reflecting their growth characteristics and genetic architectures.

Constructs, Libraries, and Mutant Populations

Test items also include plasmid constructs, CRISPR editing cassettes, promoter and terminator libraries, combinatorial pathway libraries, and mutagenized cell populations generated by UV, chemical, or atmospheric and room temperature plasma (ARTP) treatment. Library samples are characterized for diversity, coverage, and transformation efficiency before screening begins.

Reference and Control Materials

Each study incorporates parental wild-type strains, known positive-performance controls, and negative controls to verify assay sensitivity, selectivity, and reproducibility across screening batches.

Testing Items

Testing programs are structured to answer four core questions: is the intended genetic change present, does the engineered strain express the target trait, is the trait stable and scalable, and does the strain meet biosafety and identity expectations. Standard testing items include:

• Construct verification: plasmid integrity mapping, restriction analysis, insert orientation, and full insert Sanger sequencing
• Genotype confirmation: colony PCR, junction PCR, amplicon sequencing, whole-genome sequencing for off-target assessment, and gene copy number determination
• Gene and protein expression: RT-qPCR transcript quantification, SDS-PAGE, Western blot, and ELISA for target protein accumulation
• Phenotypic performance: enzyme activity assays, product titer and yield, substrate conversion rate, and by-product profiling
• Growth and physiology: growth curves, biomass yield, sporulation behavior, oxygen demand, pH and temperature tolerance, and inhibitor resistance
• Genetic stability: serial sub-cultivation over 50 to 100 generations with end-point genotyping and performance retesting
• Strain identity: 16S rRNA or ITS region sequencing, MALDI-TOF mass spectrometric identification, and strain-level typing
• Biosafety attributes: antibiotic resistance marker profiling, marker-free status confirmation, plasmid retention, and virulence factor screening

Testing Methods

Molecular Construction Techniques

Targeted construction employs CRISPR-Cas9 and Cas12a editing, lambda-Red recombineering, Cre-loxP marker recycling, homologous recombination in yeasts and filamentous fungi, and Agrobacterium-mediated transformation where appropriate. Randomized improvement employs UV irradiation, EMS chemical mutagenesis, ARTP mutagenesis, genome shuffling, and adaptive laboratory evolution under defined selection pressure.

High-Throughput Screening Assays

Primary screening uses chromogenic and fluorogenic agar assays, halo-zone measurement for secreted enzymes, indicator plates for organic acid and amino acid production, and 96- or 384-well microplate assays read by spectrophotometry and fluorescence. Reporter systems based on fluorescent proteins, luciferase, and transcription-factor biosensors enable function-driven selection, while fluorescence-activated cell sorting and droplet microfluidics extend library screening capacity to millions of variants per campaign.

Analytical Verification Methods

Confirmed hits undergo quantitative verification using HPLC and LC-MS/MS for metabolites and amino acids, GC-MS for volatile products, qPCR and digital PCR for copy number and residual plasmid detection, and next-generation sequencing for comprehensive genomic confirmation. Method validation follows recognized analytical performance criteria covering linearity, precision, accuracy, limit of detection, and limit of quantification.

Fermentation Performance Evaluation

Secondary and tertiary screening is performed in shake-flask cultures and instrumented bench-scale bioreactors with controlled pH, dissolved oxygen, temperature, and fed-batch feeding strategies. Key engineering outputs include productivity, conversion yield on substrate, oxygen transfer requirements, and process robustness across replicated batches.

Quality and Biosafety Compliance

Work is conducted under documented quality systems with general microbiological examination guidance consistent with ISO 7218, culture media performance requirements consistent with ISO 11133, and laboratory biosafety management consistent with GB 19489. Biorisk management practices aligned with ISO 35001 govern containment, decontamination, and waste handling for genetically modified organisms.

Applications

Constructed and screened strains underpin product development across nearly every sector of industrial biotechnology. Representative applications include:

• Industrial enzymes: engineered proteases, amylases, lipases, cellulases, and phytases with improved activity, thermostability, and secretion efficiency
• Amino and organic acids: high-yield production strains for L-lysine, L-glutamate, L-threonine, citric acid, lactic acid, and succinic acid
• Biopharmaceuticals: recombinant protein expression platforms, antibiotic yield improvement, and engineered secondary metabolite pathways
• Biofuels and biochemicals: ethanol-, butanol-, and 1,3-propanediol-producing strains with enhanced inhibitor and stress tolerance
• Food and probiotics: robust starter cultures, bacteriocin producers, and candidate live biotherapeutic strains with confirmed genomic safety profiles
• Agriculture and environment: nitrogen-fixing and phosphate-solubilizing inoculants, biocontrol agents, and bioremediation or plastic-degrading strains

FAQ

What is the typical timeline for a strain construction and screening project?

Timelines depend on host complexity and library size. A focused single-locus editing and confirmation study typically completes within four to eight weeks, whereas full DBTL campaigns combining mutagenesis, high-throughput screening, and bioreactor validation may extend from three to six months. A detailed milestone schedule is agreed before project initiation.

How is genetic stability demonstrated?

Engineered strains are serially passaged under non-selective conditions for 50 to 100 generations, after which the target locus is re-genotyped by PCR and sequencing and product performance is re-measured. Stability is reported as the percentage of generations retaining both the intended genotype and at least 90 percent of baseline productivity.

Can marker-free and antibiotic-resistance-free strains be verified?

Yes. Verification includes PCR and sequencing across excision junctions, antibiotic susceptibility testing to confirm loss of resistance markers, and plasmid retention analysis to document chromosomal integration status required for food-grade and feed-grade applications.

How are proprietary strains and constructs protected?

Confidential strain materials are handled under strict chain-of-custody documentation, physical containment separation, and confidentiality agreements. Access to working cell banks is restricted to authorized project personnel, and materials are returned or destroyed according to sponsor instructions upon project completion.

What biosafety levels are available?

Programs are conducted in facilities operating at biosafety level 1 and 2 for risk group 1 and 2 organisms. Genetically modified organisms are managed under biorisk management systems consistent with ISO 35001, and projects involving higher-risk organisms are assessed case by case for facility suitability and regulatory authorization.

What deliverables are provided at the end of testing?

Deliverables typically include a comprehensive technical report covering construction records, screening data with hit rankings, genotyping and sequencing evidence, analytical validation data, fermentation performance summaries, and stability results, together with the confirmed strain materials and associated certificates of analysis.